LIVIVO - Das Suchportal für Lebenswissenschaften

switch to English language
Zurück zur letzten Suche Suchhistorie
Erweiterte Suche

Ihre letzten Suchen

  1. AU="Bhardwaj, Shashank"
  2. AU=Li Bo
  3. AU=Ramani Rama
  4. AU="Várnai-Händel, Alinda"
  5. AU="Kucher, Michael"
  6. AU="Blucher, E."
  7. AU="Muffels, Ruud"
  8. AU="Roufos, I"
  9. AU="Ammad Ahmad Farooqi"
  10. AU="Zawadka-Kunikowska, Monika"
  11. AU="Young, A P"
  12. AU="Danielle M. Matriano"
  13. AU="Ancona, Jennifer"
  14. AU="Abdallah G. Kfoury"
  15. AU="Zaeske, C"
  16. AU="Hammerich, Kristoff"
  17. AU="Paul J. Burgess"
  18. AU="Valek, Lucie"
  19. AU="Mandal, Surajit"
  20. AU="Krumm, Laura"
  21. AU="Shimura, Hidetoshi"
  22. AU="Munguia-Lopez, Jose Gil"
  23. AU="Eysert, Fanny"
  24. AU="Qazi Arisa, Fakhar Ali"
  25. AU="Guan, Yunshan"
  26. AU="Ayachi, Jihene"
  27. AU="Boulvard Chollet, Xavier L E"
  28. AU="Kwon, Sohee"
  29. AU=Fra-Bido Sigrid
  30. AU="Delgado, Teresa Cardoso"
  31. AU="Judy Ly"
  32. AU="E Richtig"
  33. AU="Jones, D. C."
  34. AU="Revillet, Hélène" AU="Revillet, Hélène"
  35. AU="Lee, Ji Ye"
  36. AU="Yoshinaga, Kazuaki"
  37. AU="Moturi, Krishna"
  38. AU="Loizeau, J"
  39. AU="Gentry, Matthew S"
  40. AU="Drury, Lucy S"
  41. AU="Caraman, Irina"

Suchergebnis

Treffer 1 - 3 von insgesamt 3

Suchoptionen

  1. Artikel: Predominant polarity in bipolar affective disorder and its impact on cognition and quality of life.

    Bhardwaj, Shashank / Sinha, Deoraj / Pawar, Ami / Mane, Astik

    Indian journal of psychiatry

    2023  Band 65, Heft 6, Seite(n) 641–646

    Abstract: Background: Bipolar mood disorder or bipolar affective disorder (BPAD) is a chronic illness characterized by phases of mania/hypomania, depression, or mixed episodes. The course of bipolar mood disorder is relapsing in nature. It is associated with high ...

    Abstract Background: Bipolar mood disorder or bipolar affective disorder (BPAD) is a chronic illness characterized by phases of mania/hypomania, depression, or mixed episodes. The course of bipolar mood disorder is relapsing in nature. It is associated with high comorbidity rates, a large number of premature deaths due to suicide, and a worse social and work performance. All of those characteristics entail a significant economic impact due to both direct and indirect costs and require an effective diagnostic and therapeutic approach. Lifetime prevalence of BPAD is approximately 4% worldwide. Various attempts have been made to define "predominance" of polarity in BPAD.
    Need for this study: Our study tries to highlight the existence of predominant polarity by comparing effects of the same on substance consumption, cognitive abilities, quality of life, and preponderance of specific polarity to specific gender.
    Method: After Institutional Ethics Committee Approval and written informed consent, patients who were diagnosed with BPAD attending out-patient department of a tertiary care hospital in Mumbai were recruited. A total of 57 participants were enrolled. The World Health Organization Quality of Life - Brief Scale (WHOQOL BREF) and the Montréal Cognitive Assessment (MoCA) were both used to evaluate the patients' quality of life and cognitive ability, respectively.
    Discussion and results: Men exhibited manic predominant polarity, while women had depressive predominant polarity, with
    Conclusion: Men were observed to experience more manic episodes. More women in the study experienced predominantly depressive polarity, highlighting the need to probe for a past history of hypomania or mixed episodes to avoid misdiagnosis as unipolar depression in them. Manic predominate polarity performed better in the physical and psychological domains of the post hoc test for quality-of-life BREF scale. There were substantial MoCA score differences between the groups with depressive polarity and no polarity, with the depressive polarity showing more cognitive decline.
    Sprache Englisch
    Erscheinungsdatum 2023-06-19
    Erscheinungsland India
    Dokumenttyp Journal Article
    ZDB-ID 221523-8
    ISSN 0019-5545
    ISSN 0019-5545
    DOI 10.4103/indianjpsychiatry.indianjpsychiatry_163_23
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

    Verfügbar in ZB MED Köln/Königswinter

    Zs.B 2038: Hefte anzeigen Standort:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Über subito bestellen

    Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

  2. Artikel: Role of Rituximab in Patients with Resistant Nephrotic Syndrome.

    Singh, Seetaram / Agarwal, Dhananjai / Gupta, Rakesh / Malhotra, Vinay / Bhardwaj, Shashank

    The Journal of the Association of Physicians of India

    2022  Band 70, Heft 4, Seite(n) 11–12

    Abstract: Resistant nephrotic syndrome is a group of disorders with diverse histological findings, which are by definition resistant to corticosteroids given in adequate dose for adequate duration and many are resistant to other therapy as well. In many patients ... ...

    Abstract Resistant nephrotic syndrome is a group of disorders with diverse histological findings, which are by definition resistant to corticosteroids given in adequate dose for adequate duration and many are resistant to other therapy as well. In many patients progression to end-stage renal disease is the ultimate outcome. The role of B cells has not been fully explained in man, agents that specifically interfere with B cells would ideally represent the first step toward selective therapy. We studied short term and long term effects of rituximab in patients with resistent primary nephrotic syndrome.
    Material: Study was conducted at SMS-medical college and Hospital Jaipur, four doses of rituximab were given weakly, in fixed dose of 500 mg per dose and proteinuria was evaluated before start of therapy and at 3 months, 6 months and 12 months of therapy. Patients with resistant primary nephrotic syndrome who failed to respond to other therapies, with stable eGFR >30, and controlled BP were included in study. Patients with Active infection, Uncontrolled hypertension, pregnancy were excluded from study.
    Observation: 10 patients were enrolled in study out of which 7 FSGS (focal segmental glomeruloscllerosis) and 3 were IMN (idiopathic membranous nephropathy), 5 were female and 5 were male, age 17-61years (average 34.6), weight were 48-70 kg (avg 57.9), BMI 19.4-23 (AVG 21.18), all patients have normal renal function (average creatinine value of 0.8, range= 0.5 to 1.1). At 3 months 1 patient had partial response and 9 had no response. At 6 months of treatment 2 patients had partial response, 3 had complete response and 5 no response. At 12 months of treatment 4 had partial response, 5 had complete response and 1 no response. Out of 10 patients no one had relapse of Nephrotic syndrome at 12 month of therapy. Renal function remain normal in all patients over 12 months followup.
    Conclusion: This prospective, observational study evaluated 3 month, 6 month, and 12 month outcome of 3 IMN and 7 FSGS patients, with persistent nephrotic range proteinuria and showed that rituximab promoted sustained remission in proteinuria in resistent nephrotic syndrome with normal renal function.
    Mesh-Begriff(e) Adolescent ; Adult ; Female ; Glomerulonephritis, Membranous/chemically induced ; Glomerulonephritis, Membranous/drug therapy ; Glomerulosclerosis, Focal Segmental/chemically induced ; Glomerulosclerosis, Focal Segmental/drug therapy ; Humans ; Immunosuppressive Agents/therapeutic use ; Male ; Middle Aged ; Nephrotic Syndrome/drug therapy ; Prospective Studies ; Proteinuria/drug therapy ; Proteinuria/etiology ; Rituximab/therapeutic use ; Treatment Outcome ; Young Adult
    Chemische Substanzen Immunosuppressive Agents ; Rituximab (4F4X42SYQ6)
    Sprache Englisch
    Erscheinungsdatum 2022-04-20
    Erscheinungsland India
    Dokumenttyp Journal Article ; Observational Study
    ZDB-ID 800766-4
    ISSN 0004-5772
    ISSN 0004-5772
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

    Verfügbar in ZB MED Köln/Königswinter

    Zs.B 313: Hefte anzeigen Standort:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Über subito bestellen

    Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

  3. Artikel ; Online: Oxymatrine induces cell cycle arrest and apoptosis and suppresses the invasion of human glioblastoma cells through the EGFR/PI3K/Akt/mTOR signaling pathway and STAT3.

    Dai, Zhibo / Wang, Ligang / Wang, Xiaoxiong / Zhao, Boxian / Zhao, Wenyang / Bhardwaj, Shashank Singh / Ye, Junyi / Yin, Zhiqin / Zhang, Jun / Zhao, Shiguang

    Oncology reports

    2018  Band 40, Heft 2, Seite(n) 867–876

    Abstract: Oxymatrine (OM), a natural quinolizidine alkaloid extracted from the traditional Chinese herb Sophora flavescens, has been revealed to produce antitumor activities in various cancer cell lines, including glioblastoma lines, in vitro. However, the ... ...

    Abstract Oxymatrine (OM), a natural quinolizidine alkaloid extracted from the traditional Chinese herb Sophora flavescens, has been revealed to produce antitumor activities in various cancer cell lines, including glioblastoma lines, in vitro. However, the mechanisms by which OM exerts its antitumor effect against glioma are poorly understood. The aim of this study was to investigate the role of OM in the proliferation, apoptosis and invasion of glioma cells and to reveal the underlying mechanisms. The effects of OM on U251MG cells in vitro were determined using a Cell Counting Kit‑8 (CCK‑8) assay, flow cytometric analysis, Annexin V‑FITC/PI staining, DAPI staining, a terminal deoxynucleotidyl transferase‑mediated dUTP nick end‑labeling (TUNEL) assay, a Transwell assay and western blotting. Our data indicated that OM inhibited proliferation, arrested the cell cycle at the G0/G1 phase, decreased the expression levels of G1 cell cycle regulatory proteins (cyclin D1, CDK4 and CDK6), inhibited invasion and induced apoptosis in glioma cells. Additional investigations revealed that the expression levels of p‑STAT3 and key proteins in the EGFR/PI3K/Akt/mTOR signaling pathway, such as p‑EGFR, p‑Akt and p‑mTOR, were markedly decreased after OM treatment, while the total STAT3, EGFR, Akt and mTOR levels were not affected. These findings indicated that the EGFR/PI3K/Akt/mTOR signaling pathway and STAT3 suppression may be a potential mechanism of the OM‑mediated antitumor effect in glioblastoma cells and that EGFR may be a target of OM. Hence, OM may be a promising drug and may offer a novel therapeutic strategy for malignant gliomas in the future.
    Mesh-Begriff(e) Alkaloids/pharmacology ; Alkaloids/therapeutic use ; Antineoplastic Agents/pharmacology ; Antineoplastic Agents/therapeutic use ; Apoptosis/drug effects ; Cell Line, Tumor ; Cell Proliferation/drug effects ; G1 Phase Cell Cycle Checkpoints/drug effects ; Glioblastoma/drug therapy ; Glioblastoma/pathology ; Humans ; Neoplasm Invasiveness ; Phosphatidylinositol 3-Kinases/metabolism ; Proto-Oncogene Proteins c-akt/metabolism ; Quinolizines/pharmacology ; Quinolizines/therapeutic use ; Receptor, Epidermal Growth Factor/metabolism ; STAT3 Transcription Factor/metabolism ; Signal Transduction/drug effects ; Sophora/chemistry ; TOR Serine-Threonine Kinases/metabolism
    Chemische Substanzen Alkaloids ; Antineoplastic Agents ; Quinolizines ; STAT3 Transcription Factor ; STAT3 protein, human ; oxymatrine (85U4C366QS) ; Phosphatidylinositol 3-Kinases (EC 2.7.1.-) ; MTOR protein, human (EC 2.7.1.1) ; TOR Serine-Threonine Kinases (EC 2.7.1.1) ; EGFR protein, human (EC 2.7.10.1) ; Receptor, Epidermal Growth Factor (EC 2.7.10.1) ; Proto-Oncogene Proteins c-akt (EC 2.7.11.1)
    Sprache Englisch
    Erscheinungsdatum 2018-06-20
    Erscheinungsland Greece
    Dokumenttyp Journal Article
    ZDB-ID 1222484-4
    ISSN 1791-2431 ; 1021-335X
    ISSN (online) 1791-2431
    ISSN 1021-335X
    DOI 10.3892/or.2018.6512
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

    Verfügbar in ZB MED Köln/Königswinter

    Zs.A 4213: Hefte anzeigen Standort:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Über subito bestellen

    Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

Zum Seitenanfang